Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430738 · ClinicalTrials.gov registry record · Phase 2
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
A Phase 2 study of Cholangiocarcinoma and Colorectal Carcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT04430738 is a Phase 2 study of Cholangiocarcinoma and Colorectal Carcinoma that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 40 participants, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04430738, a Phase 2 study of Cholangiocarcinoma and Colorectal Carcinoma, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer. It will also look at whether tucatinib works with these drugs to treat certain types of cancer. The participants in this trial have HER2-positive (HER2+) cancer in their gut, stomach, intestines, or gallbladder (gastrointestinal cancer).
Conditions Studied
Interventions
- DRUG tucatinib
- DRUG trastuzumab
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin
Study Locations (20)
Missouri
- Siteman Cancer Center - St Peters - City of Saint Peters
- Siteman Cancer Center - West County - Creve Coeur
- Siteman Cancer Center - North County - Florissant
- Siteman Cancer Center - St Louis
- Barnes-Jewish Hospital - St Louis
- Washington University School of Medicine - St Louis
- Siteman Cancer Center - South County - St Louis
Colorado
- University of Colorado Denver CTO(CTRC) - Aurora
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) - Aurora
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) - Aurora
- PCM Trials - Denver
Arizona
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic - Scottsdale
North Carolina
- Duke University Medical Center, Duke Cancer Center - Durham
- Duke University Medical Center - Durham
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
New Mexico
- University of New Mexico Comprehensive Cancer Center - Albuquerque
Ohio
- Cleveland Clinic - Cleveland
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04430738
The ClinicalTrials.gov registry entry for NCT04430738 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which tucatinib is the first listed.
NCT04430738 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Missouri, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT04430738 about?
NCT04430738 is a clinical study titled "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers". This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating ca...
What is the current status of trial NCT04430738?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-09-15. Estimated completion is 2026-12-31.
What conditions does trial NCT04430738 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Colorectal Carcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gallbladder Carcinoma.
What interventions are being tested in trial NCT04430738?
The interventions under investigation include: tucatinib (DRUG), trastuzumab (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin (DRUG).
Who is sponsoring clinical trial NCT04430738?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04430738 being conducted?
This trial has 20 study locations across Arizona, Colorado, District of Columbia, Missouri, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
-
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
RECRUITING · Phase 2
-
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.